CRINETICS PHARMACEUTICALS IN (CRNX) Fundamental Analysis & Valuation

NASDAQ:CRNX • US22663K1079

Current stock price

37.49 USD
+0.98 (+2.68%)
At close:
37.49 USD
0 (0%)
After Hours:

This CRNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRNX Profitability Analysis

1.1 Basic Checks

  • In the past year CRNX has reported negative net income.
  • CRNX had a negative operating cash flow in the past year.
  • In the past 5 years CRNX always reported negative net income.
  • CRNX had a negative operating cash flow in each of the past 5 years.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M -500M

1.2 Ratios

  • CRNX's Return On Assets of -41.32% is in line compared to the rest of the industry. CRNX outperforms 41.45% of its industry peers.
  • Looking at the Return On Equity, with a value of -46.90%, CRNX is in line with its industry, outperforming 53.37% of the companies in the same industry.
Industry RankSector Rank
ROA -41.32%
ROE -46.9%
ROIC N/A
ROA(3y)-31.96%
ROA(5y)-34.62%
ROE(3y)-36.41%
ROE(5y)-38.7%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • CRNX has a better Gross Margin (86.02%) than 89.12% of its industry peers.
  • The Profit Margin and Operating Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CRNX Health Analysis

2.1 Basic Checks

  • CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRNX has been increased compared to 1 year ago.
  • Compared to 5 years ago, CRNX has more shares outstanding
  • CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • CRNX has an Altman-Z score of 14.85. This indicates that CRNX is financially healthy and has little risk of bankruptcy at the moment.
  • CRNX's Altman-Z score of 14.85 is amongst the best of the industry. CRNX outperforms 87.05% of its industry peers.
  • There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.85
ROIC/WACCN/A
WACC9.49%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 12.32 indicates that CRNX has no problem at all paying its short term obligations.
  • The Current ratio of CRNX (12.32) is better than 81.87% of its industry peers.
  • CRNX has a Quick Ratio of 12.30. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 12.30, CRNX belongs to the best of the industry, outperforming 81.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.32
Quick Ratio 12.3
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CRNX Growth Analysis

3.1 Past

  • CRNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.15%.
  • CRNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 640.71%.
  • The Revenue has been growing by 156.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-33.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.59%
Revenue 1Y (TTM)640.71%
Revenue growth 3Y17.53%
Revenue growth 5Y156%
Sales Q2Q%N/A

3.2 Future

  • CRNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.83% yearly.
  • CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 202.19% yearly.
EPS Next Y-0.75%
EPS Next 2Y6.56%
EPS Next 3Y18.03%
EPS Next 5Y22.83%
Revenue Next Year890.39%
Revenue Next 2Y426.12%
Revenue Next 3Y304.35%
Revenue Next 5Y202.19%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRNX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
  • Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRNX's earnings are expected to grow with 18.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.56%
EPS Next 3Y18.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRNX Dividend Analysis

5.1 Amount

  • No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRNX Fundamentals: All Metrics, Ratios and Statistics

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (3/13/2026, 8:18:42 PM)

After market: 37.49 0 (0%)

37.49

+0.98 (+2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners109.28%
Inst Owner Change7.04%
Ins Owners1.7%
Ins Owner Change14.38%
Market Cap3.93B
Revenue(TTM)7.70M
Net Income(TTM)-465.32M
Analysts84.55
Price Target86.34 (130.3%)
Short Float %14.23%
Short Ratio11.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.12%
Min EPS beat(2)-7.76%
Max EPS beat(2)7.51%
EPS beat(4)1
Avg EPS beat(4)-4.59%
Min EPS beat(4)-9.79%
Max EPS beat(4)7.51%
EPS beat(8)2
Avg EPS beat(8)-4.84%
EPS beat(12)2
Avg EPS beat(12)-5.53%
EPS beat(16)3
Avg EPS beat(16)-6.03%
Revenue beat(2)1
Avg Revenue beat(2)-16.98%
Min Revenue beat(2)-61.44%
Max Revenue beat(2)27.48%
Revenue beat(4)3
Avg Revenue beat(4)234.47%
Min Revenue beat(4)-61.44%
Max Revenue beat(4)682.52%
Revenue beat(8)4
Avg Revenue beat(8)107.51%
Revenue beat(12)7
Avg Revenue beat(12)139.16%
Revenue beat(16)9
Avg Revenue beat(16)121.87%
PT rev (1m)0%
PT rev (3m)5.61%
EPS NQ rev (1m)9%
EPS NQ rev (3m)12.95%
EPS NY rev (1m)3.29%
EPS NY rev (3m)7.87%
Revenue NQ rev (1m)7.64%
Revenue NQ rev (3m)31.1%
Revenue NY rev (1m)3.36%
Revenue NY rev (3m)12.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 510.08
P/FCF N/A
P/OCF N/A
P/B 3.96
P/tB 3.96
EV/EBITDA N/A
EPS(TTM)-4.94
EYN/A
EPS(NY)-4.98
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS0.07
BVpS9.47
TBVpS9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.32%
ROE -46.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.02%
FCFM N/A
ROA(3y)-31.96%
ROA(5y)-34.62%
ROE(3y)-36.41%
ROE(5y)-38.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 148.12%
Cap/Sales 74.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.32
Quick Ratio 12.3
Altman-Z 14.85
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)237.7%
Cap/Depr(5y)186.06%
Cap/Sales(3y)187.22%
Cap/Sales(5y)127.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.59%
EPS Next Y-0.75%
EPS Next 2Y6.56%
EPS Next 3Y18.03%
EPS Next 5Y22.83%
Revenue 1Y (TTM)640.71%
Revenue growth 3Y17.53%
Revenue growth 5Y156%
Sales Q2Q%N/A
Revenue Next Year890.39%
Revenue Next 2Y426.12%
Revenue Next 3Y304.35%
Revenue Next 5Y202.19%
EBIT growth 1Y-52.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.7%
EBIT Next 3Y16.01%
EBIT Next 5YN/A
FCF growth 1Y-63.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.18%
OCF growth 3YN/A
OCF growth 5YN/A

CRINETICS PHARMACEUTICALS IN / CRNX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CRINETICS PHARMACEUTICALS IN (CRNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRNX.


Can you provide the valuation status for CRINETICS PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.


What is the profitability of CRNX stock?

CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.